AU2013232014B2 - An iloperidone metabolite for use in the treatment of psychiatric disorders - Google Patents
An iloperidone metabolite for use in the treatment of psychiatric disorders Download PDFInfo
- Publication number
- AU2013232014B2 AU2013232014B2 AU2013232014A AU2013232014A AU2013232014B2 AU 2013232014 B2 AU2013232014 B2 AU 2013232014B2 AU 2013232014 A AU2013232014 A AU 2013232014A AU 2013232014 A AU2013232014 A AU 2013232014A AU 2013232014 B2 AU2013232014 B2 AU 2013232014B2
- Authority
- AU
- Australia
- Prior art keywords
- day
- once daily
- pharmaceutically acceptable
- ester
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical class COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 title claims description 42
- 208000020016 psychiatric disease Diseases 0.000 title claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 208000035475 disorder Diseases 0.000 claims abstract description 10
- 229960003162 iloperidone Drugs 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 150000002148 esters Chemical class 0.000 claims description 14
- 238000004448 titration Methods 0.000 claims description 9
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- 208000029560 autism spectrum disease Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 2
- 208000012202 Pervasive developmental disease Diseases 0.000 claims description 2
- 208000024714 major depressive disease Diseases 0.000 claims description 2
- 208000022610 schizoaffective disease Diseases 0.000 claims description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract description 6
- 229940127236 atypical antipsychotics Drugs 0.000 abstract description 6
- 239000002552 dosage form Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000001089 Multiple system atrophy Diseases 0.000 description 4
- 206010031127 Orthostatic hypotension Diseases 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 2
- 241000167880 Hirundinidae Species 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000008841 allosteric interaction Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical class [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016203591A AU2016203591B2 (en) | 2012-03-14 | 2016-05-30 | An iloperidone metabolite for use in the treatment of psychiatric disorders |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610664P | 2012-03-14 | 2012-03-14 | |
| US61/610,664 | 2012-03-14 | ||
| PCT/US2013/031413 WO2013138602A1 (en) | 2012-03-14 | 2013-03-14 | An iloperidone metabolite for use in the treatment of psychiatric disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016203591A Division AU2016203591B2 (en) | 2012-03-14 | 2016-05-30 | An iloperidone metabolite for use in the treatment of psychiatric disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013232014A1 AU2013232014A1 (en) | 2014-09-18 |
| AU2013232014B2 true AU2013232014B2 (en) | 2016-06-16 |
Family
ID=48407766
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013232014A Active AU2013232014B2 (en) | 2012-03-14 | 2013-03-14 | An iloperidone metabolite for use in the treatment of psychiatric disorders |
| AU2016203591A Active AU2016203591B2 (en) | 2012-03-14 | 2016-05-30 | An iloperidone metabolite for use in the treatment of psychiatric disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016203591A Active AU2016203591B2 (en) | 2012-03-14 | 2016-05-30 | An iloperidone metabolite for use in the treatment of psychiatric disorders |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10874659B2 (ru) |
| EP (2) | EP2825167B1 (ru) |
| JP (5) | JP2015510893A (ru) |
| KR (2) | KR20170008327A (ru) |
| CN (2) | CN104203240A (ru) |
| AU (2) | AU2013232014B2 (ru) |
| BR (1) | BR112014022687A8 (ru) |
| CA (1) | CA2865845C (ru) |
| CL (1) | CL2014002430A1 (ru) |
| CO (1) | CO7091183A2 (ru) |
| ES (2) | ES2677474T3 (ru) |
| IL (1) | IL234412B (ru) |
| IN (1) | IN2014DN08495A (ru) |
| MX (1) | MX2014010989A (ru) |
| RU (1) | RU2651710C2 (ru) |
| WO (1) | WO2013138602A1 (ru) |
| ZA (1) | ZA201406369B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116211857A (zh) | 2015-02-17 | 2023-06-06 | 万达制药公司 | 用于治疗精神分裂症的伊潘立酮 |
| US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003020707A1 (en) * | 2001-08-31 | 2003-03-13 | Novartis Ag | Optical isomers of an iloperidone metabolite |
| WO2005030763A1 (en) * | 2003-10-01 | 2005-04-07 | Novartis Ag | Benzisoxazoles |
| US20090306137A1 (en) * | 2006-05-22 | 2009-12-10 | Wolfgang Curt D | Treatment for depressive disorders |
| WO2010030783A1 (en) * | 2008-09-10 | 2010-03-18 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| ATE503845T1 (de) | 2001-12-10 | 2011-04-15 | Novartis Pharma Gmbh | Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen |
| TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
| AU2005292246B2 (en) | 2004-09-30 | 2011-07-07 | Vanda Pharmaceuticals, Inc | Methods for the administration of iloperidone |
| ES2542967T3 (es) | 2007-03-29 | 2015-08-13 | Vanda Pharmaceuticals Inc. | Método de predecir una predisposición a la prolongación de QT |
| EP2198049A1 (en) | 2007-09-10 | 2010-06-23 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on snp genotype |
| JP5653753B2 (ja) | 2007-09-10 | 2015-01-14 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Ｓｎｐ遺伝子型に基づくｑｔ延長の予測 |
| ES2673603T3 (es) | 2009-04-06 | 2018-06-25 | Vanda Pharmaceuticals Inc. | Método de tratamiento basado en polimorfismos del gen KCNQ1 |
| JP5881598B2 (ja) | 2009-04-06 | 2016-03-09 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Ａｂｃｃ２遺伝子の配列又はその産物に基づいてｑｔ延長に対する素因を予測する方法 |
| CA2757717C (en) | 2009-04-06 | 2018-09-04 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation |
| US9072742B2 (en) | 2009-04-06 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
| CA2760474C (en) | 2009-05-15 | 2020-08-18 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on drd2 or ankk1 snp genotype |
-
2013
- 2013-03-14 US US14/384,401 patent/US10874659B2/en active Active
- 2013-03-14 ES ES13721817.8T patent/ES2677474T3/es active Active
- 2013-03-14 IN IN8495DEN2014 patent/IN2014DN08495A/en unknown
- 2013-03-14 ES ES18152636T patent/ES2773711T3/es active Active
- 2013-03-14 CN CN201380013841.XA patent/CN104203240A/zh active Pending
- 2013-03-14 JP JP2015500615A patent/JP2015510893A/ja active Pending
- 2013-03-14 KR KR1020177001093A patent/KR20170008327A/ko active Search and Examination
- 2013-03-14 CN CN201810683727.2A patent/CN108938632A/zh active Pending
- 2013-03-14 WO PCT/US2013/031413 patent/WO2013138602A1/en active Application Filing
- 2013-03-14 MX MX2014010989A patent/MX2014010989A/es active IP Right Grant
- 2013-03-14 EP EP13721817.8A patent/EP2825167B1/en active Active
- 2013-03-14 CA CA2865845A patent/CA2865845C/en active Active
- 2013-03-14 EP EP18152636.9A patent/EP3345603B1/en active Active
- 2013-03-14 AU AU2013232014A patent/AU2013232014B2/en active Active
- 2013-03-14 BR BR112014022687A patent/BR112014022687A8/pt not_active Application Discontinuation
- 2013-03-14 KR KR1020147026434A patent/KR20140121487A/ko active Search and Examination
- 2013-03-14 RU RU2014141112A patent/RU2651710C2/ru active
-
2014
- 2014-08-29 ZA ZA2014/06369A patent/ZA201406369B/en unknown
- 2014-09-01 IL IL234412A patent/IL234412B/en active IP Right Grant
- 2014-09-12 CL CL2014002430A patent/CL2014002430A1/es unknown
- 2014-10-09 CO CO14224666A patent/CO7091183A2/es unknown
-
2016
- 2016-05-30 AU AU2016203591A patent/AU2016203591B2/en active Active
- 2016-11-07 JP JP2016217680A patent/JP2017061506A/ja active Pending
-
2018
- 2018-09-10 JP JP2018169090A patent/JP7151029B2/ja active Active
-
2020
- 2020-09-28 JP JP2020162569A patent/JP2021001221A/ja active Pending
- 2020-09-30 US US17/039,769 patent/US20210015809A1/en not_active Abandoned
-
2022
- 2022-12-01 JP JP2022192922A patent/JP2023022243A/ja active Pending
-
2023
- 2023-09-26 US US18/373,205 patent/US20240016791A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003020707A1 (en) * | 2001-08-31 | 2003-03-13 | Novartis Ag | Optical isomers of an iloperidone metabolite |
| WO2005030763A1 (en) * | 2003-10-01 | 2005-04-07 | Novartis Ag | Benzisoxazoles |
| US20090306137A1 (en) * | 2006-05-22 | 2009-12-10 | Wolfgang Curt D | Treatment for depressive disorders |
| WO2010030783A1 (en) * | 2008-09-10 | 2010-03-18 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
Non-Patent Citations (3)
| Title |
|---|
| ALBERS LJ, et al., Expert Opin. Invest. Drugs, (2008), Vol 17(1), pp 61-75. * |
| CACCIA S, et al., Drug Design, Development and Therapy, (2010), Vol 4, pp33-48. * |
| SUBRAMANIAN N, et al., Progress in Neuro-Psychopharmacology & Biological Psychiatry, (2002), Vol 26, pp 553-560. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240016791A1 (en) | Iloperidone metabolite for use in the treatment of psychiatric disorders | |
| US20090068290A1 (en) | Bifeprunox doses for treating schizophrenia | |
| CA2641917A1 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
| WO2006096435A1 (en) | Pharmaceutical compositions for the treatment and/or prevention of depression | |
| US9839627B2 (en) | Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder | |
| CA2682015A1 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
| KR20210139293A (ko) | 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여 | |
| WO2008025781A1 (en) | Bifeprunox doses for treating schizophrenia | |
| JP7208139B2 (ja) | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| JP2021530488A (ja) | 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール | |
| MXPA02003452A (es) | Tratamiento de combinacion de esclerosis multiple (em), otras condiciones de desmielinacion y neuropatia periferica, especialmente neuropatias dolorosas y neuropatia diabetica. | |
| JP2018035086A (ja) | 低活動膀胱の予防及び／又は治療薬 | |
| WO2005117853A1 (ja) | 高脂血症治療剤及び糖尿病治療剤 | |
| JP2000212091A (ja) | 消化管機能異常治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |